Phase 2 Stroke Trial, Recruiting NCT05653440 Sponsor: University of Pittsburgh Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT05653440
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with aphasia (difficulty with language and communication) lasting more than 6 months, caused by a stroke that affected the left side of the brain.
  • People whose results on a specific language assessment test (the Comprehensive Aphasia Test) show difficulties in at least 2 out of 8 areas tested.

Who may not be able to join:

  • People who have a history of other brain or nervous system conditions that were either acquired (such as a brain injury) or are progressive (such as a degenerative disease).
  • People who have significant difficulties understanding language.
  • People who have a drug or alcohol dependence that is not currently being managed or treated.
  • People who have been diagnosed with a serious mood or behavioural disorder that requires specialised mental health treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: William Evans, PhD, University of Pittsburgh

Phone: 412-648-3274

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
27 November 2023
Est. completion
31 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in correct responses in Confrontation Naming of Treated Pictured Objects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov